Fig. 4. Treatment of VP1/CRA resulted in activation of effective T cells in CMS5-VP1 tumor-bearing mice.

a Treatment schedule was depicted. Naive BALB/c mice were subcutaneously inoculated with CMS5-VP1 tumor cells (1 × 10⁶ per mice) in the left flank back on day 0. When tumors were palpable, tumor-bearing mice were randomly divided into five per group and immunized thrice starting from day 5 with 1-week intervals. b Percentage of IL-2, TNF-α, and IFN-γ expressing CD4⁺or CD8⁺T cells in Figure 3A were statistically analyzed with ordinary one-way ANOVA. c Percentage of CD4⁺Tregs cells in Figure 3B. d Percentage of TGF-β Tregs in Figure 3B. P: 0.1234(NS), 0.0332(*), 0.0021(**), 0.0002(***), <0.0001(****).